Bain Capital Life Sciences Investors, LLC bought $1.7M of Olema Pharmaceuticals (OLMA)
Executed Jan 8 2025, disclosed Jan 13 2025, 5 days later, against a two-business-day limit.
Over the 21 trading sessions from the disclosed entry session (Jan 13 2025), the stock returned +6.5% (delay-adjusted); from the execution session (Jan 8 2025), +8.0%. Derived: entry at the session's open, exit at the close 20 sessions later.
Bain Capital Life Sciences Investors, LLC (10% owner) filed 2 Form 4 reports as a reporting entity in the trailing twelve months (1 purchase, 1 sale), most often in Heartflow, Inc. (HTFL). Across 1 priced purchase filing, the average 21-session return was -26.2% from execution and -26.2% from disclosure (delay-adjusted; derived). The largest single filing was $56.1M of HTFL (2,000,000 sh × $28.05, as filed), executed Feb 4.
Healthcare · Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of th…
More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→